Literature DB >> 3056613

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.

P J Elson1, R S Witte, D L Trump.   

Abstract

A data base study of 610 patients with recurrent or metastatic renal cell carcinoma was conducted in order to identify clinical characteristics that are prognostic for survival in patients with this disease. Multivariate analysis identified initial Eastern Cooperative Oncology Group performance status (0 versus 1 versus 2 versus 3), time from initial diagnosis (greater than 1 year versus less than or equal to 1 year), number of metastatic sites (0,1 versus greater than 1), prior cytotoxic chemotherapy (no versus yes), and recent weight loss (no versus yes) as important indicators of survival. Closer examination of the resulting model indicated that patients can easily be separated into five prognostic subgroups, the subgroups being defined by a simple function of the number of risk factors present [Eastern Cooperative Oncology Group performance status 1, recent diagnosis (less than or equal to 1 year), greater than 1 metastatic site, recent weight loss, and prior cytotoxic chemotherapy each counting as a single risk factor; and Eastern Cooperative Oncology Group performance status 2 and 3 counting as 2 and 3 risk factors, respectively]. Median survival for each of the five risk groups was 12.8, 7.7, 5.3, 3.4, and 2.1 months, respectively.

Entities:  

Mesh:

Year:  1988        PMID: 3056613

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

Review 1.  Immunotherapy for renal carcinoma: theoretical basis and current standard of care.

Authors:  P A Vasey
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 2.  The role of resection for patients with renal carcinoma.

Authors:  R C Flanigan; P M Yonover
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

3.  Best of the 2001 AUA Annual Meeting: Highlights of the 2001 Annual Meeting of the American Urological Association June 2-7, 2001, Anaheim, CA.

Authors: 
Journal:  Rev Urol       Date:  2001

4.  Cytoreductive nephrectomy: a treatment of the past.

Authors:  Peter Venner
Journal:  Can Urol Assoc J       Date:  2010-02       Impact factor: 1.862

5.  Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.

Authors:  Sylvie Negrier; Frédéric Gomez; Jean-Yves Douillard; Alain Ravaud; Christine Chevreau; Murielle Buclon; David Perol; Christine Lasset; Bernard Escudier
Journal:  World J Urol       Date:  2005-02-12       Impact factor: 4.226

Review 6.  Tumors of the kidney, ureter, and bladder.

Authors:  W A See; R D Williams
Journal:  West J Med       Date:  1992-05

7.  Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).

Authors:  Janice P Dutcher; Jason P Fine; Robert L Krigel; Barbara A Murphy; Paul L Schaefer; Marc S Ernstoff; Patrick J Loehrer
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

Review 8.  Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients.

Authors:  Tracy M Downs; Matthew Schultzel; Helen Shi; Catherine Sanders; Zunera Tahir; Georgia Robins Sadler
Journal:  Crit Rev Oncol Hematol       Date:  2008-11-06       Impact factor: 6.312

9.  Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma.

Authors:  C Lasset; Y Merrouche; S Negrier; P Rebattu; J Berille; J P Bizzari; F Chauvin; T Philip
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Metastatic renal carcinoma comprehensive prognostic system.

Authors:  J Atzpodien; P Royston; T Wandert; M Reitz
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.